Embryonic-like human extracellular matrix - Histogen

Drug Profile

Embryonic-like human extracellular matrix - Histogen

Alternative Names: hECM - Histogen

Latest Information Update: 12 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Histogen
  • Class Antineoplastics; Extracellular matrix proteins
  • Mechanism of Action Apoptosis stimulants; Caspase 9 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 12 Aug 2016 Embryonic-like human extracellular matrix - Histogen is available for licensing as of 12 Aug 2016. http://www.histogen.com/
  • 12 Aug 2016 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top